Avalyn Pharma Inc. AVLN
An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Avalyn Pharma Inc.
read at $28.30
Avalyn Pharma Inc. sits unlabelled at $28.30. The next dated read will name it.
- PHPhase · no phase label on file yet
- INInsiders · no filings inside 60 days, left as found
- POPositioning · no disclosures inside 60 days, left as found
- OPOptions · no verdict drawn today, left as found
- SCScreen · screen not yet scored
- edge confirmed
- edge broken
- edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
The investor read · the season, not the day
| Phase | Unlabelled |
| Price | $28.30 |
| Valuation | N/A trailing · -14.89 forward price to earnings |
| Values screen | Not scored · score 70.0 |
| Beta | N/A |
The opportunity · what the numbers say it is worth
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
| Profit margin | 0.00% |
| Debt to equity | 15.20 |
| Analyst consensus | None · 4 covering |
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
The values screen, explained · five checks, plain English
This security has not been fully scored against the values screen yet.
- Business activity Its core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
- Debt load Interest-bearing debt is of its assets, above the one-third ceiling the screen allows. Fail
- Interest-bearing cash Interest-bearing cash and securities are of assets, above the one-third limit. Fail
- Receivables Money owed to the company is of assets, above the 49% limit. Fail
- Revenue purity of revenue comes from non-compliant sources, over the 5% line. Fail
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
The business, in plain words · what the numbers mean
Early stage lung drug firm lacks basic data
Avalyn is trying to turn common pills for lung scarring into inhaled versions that reach the disease faster and with fewer side effects. The idea sounds neat on paper, yet the company is still years from revenue and shows zero profit margin alongside a negative forward earnings multiple. Opportunity rating sits at none and the ethical screen returns insufficient data because standard financial ratios are unavailable.
That gap matters. Without those numbers we cannot judge cash burn, balance sheet strength or governance track record, so the position fails our basic filters even before clinical risk enters the picture. Four analysts carry a median target near fair value, but the absence of usable ratios leaves the story untestable.
Development of inhaled medicines for rare lung conditions carries high failure rates at every trial stage. Currency or reimbursement issues matter less here than the simple fact that most candidates never reach patients. Analysis, not advice.
| Forward P/E | -14.9x |
| Profit margin | 0.0% currently unprofitable |
| Debt to equity | 0.15 minimal debt — a conservative balance sheet |
| Current ratio | 11.03 comfortably covers its short-term bills |
| Market cap | $1.3B |
| Employees | 50 |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Related securities · others in AVLN's space worth a look
Screened names in the same industry · explore each on its own page.
Where & how to trade · wherever in the world you are
AVLN trades on Nasdaq. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The trader read · the latest dated commentary
What holding actually paid · price plus dividends
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $29.57 | +0.6% | · | $1,006 | +0.6% |
Historical returns from market close data. Past performance does not guarantee future results.